ReviewInflammatory bowel diseases2008
Leukocyte adhesion molecules in animal models of inflammatory bowel disease.
Review in Inflammatory bowel diseases, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 65 citations in OpenAlex.
- Keratinocytes regulate intraepithelial lymphocytes homing and mediate mucosal barrier integrity via JAK2/STAT3 signaling in oral lichen planus.Frontiers in immunology · 2026Article
- Expression of CD44 and Its Spliced Variants: Innate and Inducible Roles in Nervous Tissue Cells and Their Environment.International journal of molecular sciences · 2025Review
- Cell Membrane-Coated Nanotherapeutics for the Targeted Treatment of Acute and Chronic Colitis.Biomaterials research · 2024Article
- Osthole inhibits the migration and invasion of highly metastatic breast cancer cells by suppressing ITGα3/ITGβ5 signaling.Acta pharmacologica Sinica · 2022Article
- Identification of Differentially Expressed Genes and miRNAs for Ulcerative Colitis Using Bioinformatics Analysis.Frontiers in genetics · 2022Article
- Bile acids modulate colonic MAdCAM-1 expression in a murine model of combined cholestasis and colitis.Mucosal immunology · 2021Article
- Immunohistochemical Study of Adhesion Molecules in Irritable Bowel Syndrome: A Comparison to Inflammatory Bowel Diseases.Advanced biomedical research · 2021Article
- Interaction between ICAM1 in endothelial cells and LFA1 in T cells during the pathogenesis of experimental Parkinson's disease.Experimental and therapeutic medicine · 2020Article
- Evaluation of novel serological markers and autoantibodies in dogs with inflammatory bowel disease.Journal of veterinary internal medicine · 2020Article
- Topical Therapy with Antisense Tumor Necrosis Factor Alpha Using Novel β-Glucan-Based Drug Delivery System Ameliorates Intestinal Inflammation.International journal of molecular sciences · 2020Article
- Cell Trafficking Interference in Inflammatory Bowel Disease: Therapeutic Interventions Based on Basic Pathogenesis Concepts.Inflammatory bowel diseases · 2019Review
- Oligonucleotides-A Novel Promising Therapeutic Option for IBD.Frontiers in pharmacology · 2019Review
- Integrins as therapeutic targets in the organ-specific metastasis of human malignant melanoma.Journal of experimental & clinical cancer research : CR · 2018Review
- Experimental pericardial tamponade-translation of a clinical problem to its large animal model.Turkish journal of surgery · 2018Article
- Dysfunction of Cerebrovascular Endothelial Cells: Prelude to Vascular Dementia.Frontiers in aging neuroscience · 2018Review
- High endothelial venules associated with T cell subsets in the inflamed gut of newly diagnosed inflammatory bowel disease patients.Clinical and experimental immunology · 2017Article
- Alicaforsen, an antisense inhibitor of ICAM-1, as treatment for chronic refractory pouchitis after proctocolectomy: A case series.United European gastroenterology journal · 2016Article
- T-cell trafficking and anti-adhesion strategies in inflammatory bowel disease: current and future prospects.Drugs · 2014Review
- Article
- Adhesion molecules in CNS disorders: biomarker and therapeutic targets.CNS & neurological disorders drug targets · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
The dysregulated recruitment of leukocytes into the intestine is required for the initiation and maintenance of inflammatory bowel disease (IBD). Several families of molecules regulate the influx of these cells into sites of inflammation. Interference with some of these molecules has already shown efficacy in the clinics and antibodies that target the molecules involved have been approved by the FDA for use in Crohn's disease (CD), multiple sclerosis (i.e., natalizumab), and psoriasis (i.e., efalizumab). Here, we discuss basic aspects of the different families of relevant molecules and compile a large body of preclinical studies that supported the targeting of specific steps of the leukocyte adhesion cascade for therapeutic purposes in colitis and in novel models of CD-like ileitis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.